TITLE

Bendamustine: A Viewpoint by Michael Herold

AUTHOR(S)
Herold, M.
PUB. DATE
March 2001
SOURCE
Drugs;Mar2001, Vol. 61 Issue 5, p639
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Provides information on the use and effectiveness of bendamustine in the palliative treatment of non-Hodgkin's lymphomas (NHL). Development of the drug; Testing of the drug; Toxicity profile of the drug.
ACCESSION #
4386939

 

Related Articles

  • 2-Chlorodeoxyadenosine-induced complete remissions in Langerhans-cell histiocytosis. Saven, Alan; Foon, Kenneth A.; Piro, Lawrence D.; Saven, A; Foon, K A; Piro, L D // Annals of Internal Medicine;9/15/94, Vol. 121 Issue 6, p430 

    Provides information on a study that used 2-Chlorodeoxyadenosine for the treatment of several patients with Langerhans-cell histiocytosis. Methodologies used; Results and discussion.

  • Multidrug regimen boosts responses to bexarotene. Guttman, Cheryl // Dermatology Times;Dec2001, Vol. 22 Issue 12, p18 

    Focuses on improvement of the response rate of patients with cutaneous T-cell lymphoma (CTCL) to bexarotene. Purpose of current treatment of CTCL; Management of treatment-related metabolic effects; Dosage of bexarotene for patients with advanced disease.

  • Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Fisher, Richard I.; DeVita, Vincent T.; Hubbard, Susan M.; Longo, Dan L.; Wesley, Robert; Chabner, Bruce A.; Young, Robert C.; Fisher, R I; DeVita, V T Jr; Hubbard, S M; Longo, D L; Wesley, R; Chabner, B A; Young, R C // Annals of Internal Medicine;Mar83, Vol. 98 Issue 3, p304 

    A new treatment program was developed in an attempt to increase the complete remission rate and survival of previously untreated patients with advanced stages of diffuse aggressive lymphomas. A flexible number of cycles of ProMACE chemotherapy (prednisone, methotrexate, doxorubicin,...

  • ODAC denies accelerated approval for pixantrone to treat NHL. Harris, Jason // Hem/Onc Today;4/25/2010, Vol. 11 Issue 8, p1 

    The article reports on the decision of the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee to reject pixantrone for the treatment of non-Hodgkin's lymphoma.

  • Alemtuzumab/pentostatin.  // Reactions Weekly;4/17/2010, Issue 1297, p9 

    The article describes the case of a 60-year-old woman who developed Epstein Barr virus-positive diffuse large B-cell lymphoma and subsequently died while receiving treatment with pentostatin and alemtuzumab.

  • Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas. Soubeyran, P; Hostein, I; Debled, M; Eghbali, H; Soubeyran, I; Bonichon, F; Astier-Gin, T; Hœrni, B // British Journal of Cancer;11/1/99, Vol. 81 Issue 5, p860 

    Bcl-2, the gene over-expressed in follicular lymphomas (FL), is able to block chemotherapy-induced apoptosis. Consequently, we wondered whether bcl-2/IgH expression variations during treatment of FL could predict the outcome of patients with t(14;18)-bearing FL. For this purpose, we used a...

  • Bexarotene tabbed for localized CTCL. Hannapel, Coriene E. // Dermatology Times;Jun2002, Vol. 23 Issue 6, p50 

    Focuses on the effectiveness of bexarotene gel for the treatment of early-stage cutaneous T-cell lymphoma. Suitability of the drug for long-term treatment; Efficacy of the gel for patients having localized disease; Percentage of patient response rate to treatment.

  • ONCOLOGY BRIEFS.  // Dermatology Times;Jul2003, Vol. 24 Issue 7, p35 

    Reports issues related to oncology as of July 2003. Approaches to advanced tumors; Development of drugs for cutaneous lymphoma.

  • Chemotherapy for large-cell lymphoma: optimism and caution. Coleman, Morton; Coleman, M // Annals of Internal Medicine;Jul85, Vol. 103 Issue 1, p140 

    Editorial. Studies the stepwise theories and principles of chemotherapy for the treatment of patients with large-cell lymphoma. Eventuality of cure for almost all patients with large-cell lymphoma; Description of chemotherapy regimens beneficial for disease-free survival rate; Role of drug...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics